The gut-liver axis plays a pivotal role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD), which is the third leading cause of hepatocellular carcinoma (HCC) worldwide. However, the link between gut microbiota and hepatocarcinogenesis remains to be clarified. The aim of this study was to explore what features of the gut microbiota are associated with HCC in patients with cirrhosis and NAFLD. A consecutive series of patients with NAFLD-related cirrhosis and HCC (group 1, 21 patients), NAFLD-related cirrhosis without HCC (group 2, 20 patients), and healthy controls (group 3, 20 patients) was studied for gut microbiota profile, intestinal permeability, inflammatory status, and circulating mononuclear cells. We finally constructed a model depicting the most relevant correlations among these features, possibly involved in hepatocarcinogenesis. Patients with HCC showed increased levels of fecal calprotectin, while intestinal permeability was similar to patients with cirrhosis but without HCC. Plasma levels of interleukin 8 (IL8), IL13, chemokine (C-C motif) ligand (CCL) 3, CCL4, and CCL5 were higher in the HCC group and associated with an activated status of circulating monocytes. The fecal microbiota of the whole group of patients with cirrhosis showed higher abundance of Enterobacteriaceae and Streptococcus and a reduction in Akkermansia. Bacteroides and Ruminococcaceae were increased in the HCC group, while Bifidobacterium was reduced. Akkermansia and Bifidobacterium were inversely correlated with calprotectin concentration, which in turn was associated with humoral and cellular inflammatory markers. A similar behavior was also observed for Bacteroides. Conclusion: Our results suggest that in patients with cirrhosis and NAFLD the gut microbiota profile and systemic inflammation are significantly correlated and can concur in the process of hepatocarcinogenesis. (Hepatology 2019;69:107-120).
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intestinal permeability, which is a hallmark of cirrhosis, exposes the liver to a great amount of bacteria and bacterial components, such as lipopolysaccharide (LPS), derived from the gut. The interaction between LPS and toll-like receptor 4 (TLR4) is crucial in the initiation and promotion of hepatocarcinogenesis through inflammation, chronic liver injury, and fibrosis. (2) (3) (4) This complex proinflammatory network triggered by gut microbes involves resident liver cells and bone marrow-derived mononuclear cells that are known to favor HCC progression through modulation of the immune response. (5, 6) Conversely, intestinal decontamination with antibiotics, gut microbiota modulation by probiotics, and inactivation of TLR4 result in reduced occurrence and growth of HCC lesions in experimental models. (2) (3) (4) 7) Furthermore, gut bacteria may contribute to this process through the modulation of bile acid metabolism. (8, 9) Apart from studies based on animal models, there is currently only one culture-based study that has reported higher levels of Escherichia coli in fecal samples of patients with cirrhosis and HCC compared to those without tumor. (10) Therefore, the role of the gut microbiota in human hepatocarcinogenesis requires further investigation.
Nonalcoholic fatty liver disease (NAFLD) is the third leading cause of HCC worldwide (11) ; in this setting, the contribution of gut microbiota in the development and evolution of liver disease to HCC could be relevant. (12) Nevertheless, NAFLD epidemics, as well as the incidence of HCC associated with NAFLD, are expected to increase in Western populations. (13) It is therefore of great clinical and scientific interest to assess how the gut microbiota is involved in hepatocarcinogenesis in these patients in order to take therapeutic measures (e.g., intestinal decontamination, probiotic and prebiotic administration, gut microbiota transplantation), as primary or secondary prevention. This study explored the qualitative and/or quantitative differences between the gut microbiota of patients with NAFLD-related cirrhosis with and without HCC and healthy subjects without liver disease tested as controls in order to assess whether any differences related to cirrhosis and/or the presence of HCC could be detected and linked with inflammatory or immunological alterations favoring hepatocarcinogenesis.
Patients and Methods
Patients with NAFLD-related liver cirrhosis were consecutively enrolled in the study. NAFLD was diagnosed by current or previous evidence of steatosis or steatohepatitis on either imaging or liver histology in the absence of secondary causes of hepatic fat accumulation and clinical history of excessive alcohol consumption (>21 standard drinks on average per week in men and >14 standard drinks on average per week in women), in association with components of the metabolic syndrome. (14) Patients with chronic viral hepatitis, autoimmune hepatitis, cholestatic disorders such as primary biliary cholangitis or primary sclerosing cholangitis, and inherited liver disorders leading to cirrhosis such as hemochromatosis, Wilson's disease, aRtiCle iNFoRMatioN:
and alpha-1 antitrypsin deficiency were excluded from the study.
In order to explore the effect of the gut-liver axis on the systemic inflammatory status and on the emergence of HCC in NAFLD, subjects with cirrhosis and a first diagnosis of HCC who were candidates for liver resection (cirrhosis with HCC, group 1) were compared to patients with cirrhosis but without HCC matched for age, degree of liver function, and severity of portal hypertension (cirrhosis no HCC, group 2) and with age-matched healthy controls (group 3). The diagnosis of HCC was histologically confirmed by means of surgical specimen after liver resection in all patients. The diagnosis of liver cirrhosis was based on histological and/or clinical findings (laboratory parameters, imaging findings, signs of portal hypertension at liver imaging or endoscopy). Healthy subjects were chosen among health care workers and their family members who had no history of liver disease and no significant alcohol consumption.
The following inclusion and exclusion criteria were adopted in all groups: Caucasian subjects on an omnivorous, Mediterranean, normocaloric diet, and with a body mass index ranging between 18.5 and 29 kg/m 2 . All subjects who were taking drugs such as antibiotics (including rifaximin), probiotics, prebiotics, proton pump inhibitors, and laxatives during the last 6 months; affected by diseases potentially influencing the gut microbiota composition (e.g., diabetes mellitus, celiac disease, inflammatory bowel diseases, diverticular disease); or with a history of cancer were excluded from the study.
A blood sample was taken from all subjects at the time of enrollment for the determination of liver function parameters, platelet count, and alpha-fetoprotein serum levels and for the quantification of plasma cytokines/chemokines, LPS, zonulin-1 (ZO1), and peripheral blood mononuclear cells (PBMCs). A stool sample was also collected for the determination of fecal calprotectin and for analysis of the gut microbiota. A detailed description of the methods used for the assessment of intestinal permeability, systemic inflammation, and the PBMC profile, as well as for fecal calprotectin assay and 16S ribosomal RNA gene sequencing, is provided in the Supporting Information.
The study was approved by the institutional review board of the Fondazione IRCCS Agostino Gemelli Hospital; all subjects provided informed consent to participate in the study.
StatiStiCal aNalySiS
Descriptive statistics were run on all data. Patients with cirrhosis and controls were compared with respect to demographic and clinical variables; Fisher's exact test was used for categorical variables and the Wilcoxon test or Kruskal-Wallis test and Dunn post hoc analysis were used for continuous variables. Spearman correlation was also used to explore the association between calprotectin, ZO1, LPS, cytokines/chemokines, and PBMCs.
Regarding the gut microbiota analysis, Simpson's Index of Diversity, which accounts for both richness and evenness, was calculated on the basic count data to assess alpha diversity for each group of patients, and the Kruskal-Wallis test was used to assess intergroup differences.
Raw data were successively processed, and taxa not seen more than three times in at least 20% of the samples were removed.
Unconstrained ordination was done to explore the relationships between patient groups. Weighted UniFrac distance was measured on data normalized by regularized logarithm transformation (15) and used for the ordination analysis (principal coordinates analysis [PCoA]). Samples were classified according to the presence of cirrhosis and of HCC; compositional differences were tested by permutational multivariate analysis of variance on the distance matrix.
Two separate analyses were performed to investigate possible differences in bacterial abundance between patients with cirrhosis and controls (groups 1 and 2 versus 3) and between patients with cirrhosis with HCC and those without (group 1 versus 2).
We first tested differences at the phylum, family, and genus levels among groups in DESeq2 using a negative binomial distribution on raw counts normalized by "size factors," which takes into account sequencing depth between samples. (15) Only taxa with a log2 fold change higher or lower than ±1.5 and a P value <0.05 after adjusting for multiple hypotheses testing with the Benjamini-Hochberg method (P adj ) were considered to have a significant differential abundance.
The three groups of patients were then compared by the linear discriminant analysis (LDA) effect size (LEfSe) method, which emphasizes both statistical significance and biological relevance. The algorithm performs a nonparametric factorial Kruskal-Wallis sum-rank test and LDA to determine statistically significant different features among taxa and estimates the effect size of the difference. (16) Differences were considered significant for adjusted P values <0.05 and a logarithmic LDA score cutoff ≥2 and were displayed in the final output.
Finally, the correlation network between ZO1, LPS, fecal calprotectin, cytokines, and chemokines significantly increased in the HCC group; key bacterial taxa emerged from LEfSe analysis (adjusted P values <0.05 and logarithmic LDA score cutoff ≥4); and PBMCs associated with inflammatory parameters were displayed using the package qgraph.
The analyses were performed using the R statistics program (version 3.4.0).
Results
Among 118 patients with liver cirrhosis undergoing liver resection at the National Cancer Institute of Milan for HCC and evaluated consecutively over a period of 1 year, 97 were excluded (8 for a previous history of HCC, 75 for chronic viral hepatitis, 14 for alcohol use/abuse or recent antibiotic treatment or proton pump inhibitors use) and 21 met the inclusion criteria (group 1). Twenty patients with NAFLDrelated cirrhosis without HCC (group 2) and 20 healthy controls (group 3) were also enrolled in the study. The characteristics of the population under study are shown in Table 1 .
Median age was comparable among groups, whereas there was a higher prevalence of men among patients with cirrhosis (groups 1 and 2) compared to healthy controls. All patients with cirrhosis presented a compensated stage of liver disease (Child-Pugh class A, median Model for End-Stage Liver Disease score 8, no ascites or hepatic encephalopathy), mostly without or with mild portal hypertension, as shown by the stage of esophageal varices and by platelet counts (<100 × 10 3 /mL). In all patients, HCC was classified as Barcelona Clinic Liver Cancer stage A (single nodule or no more than three nodules each lower than 3 cm in size). (11) On the whole, 25 HCC nodules were resected in 21 patients, and the tumor histological grading was moderately differentiated in 22 cases and poorly differentiated in 3 cases.
iNteStiNal peRMeaBility aND iNFlaMMatioN
Intestinal permeability was increased in all patients with liver cirrhosis, who had higher levels of plasma ZO1 and LPS compared to healthy controls (ZO1 groups 1 
SySteMiC iNFlaMMatioN
A specific pattern of cytokine and chemokine expression was associated with liver cirrhosis and with the presence of HCC (Table 1 ). Compared to controls, on the whole patients with cirrhosis (groups 1 and 2) presented lower plasma levels of interleukin 5 (IL5) (P = 0.026), IL17 (P = 0.036), and platelet-derived growth factor (PDGF) BB (P = 0.006) and higher plasma levels of chemokine (C-C motif ) ligand (CCL) 2 (P < 0.0001), CCL3 (P = 0.048), CCL5 (P < 0.0001), and chemokine (C-X-C motif ) ligand (CXCL) 10 (P < 0.0001). Higher plasma levels of IL8 (P = 0.015), IL13 (P = 0.005), CCL3 (P = 0.039), CCL4 (P = 0.005), and CCL5 (P = 0.016) were observed in patients with cirrhosis with HCC compared to those without (group 1 versus 2).
To evaluate whether plasma levels of cytokines could be associated with a specific activation of the immune system, we quantified circulating PBMCs in the group of patients with cirrhosis and HCC. Several correlations were found between circulating T cells, monocytes (cluster of differentiation 14- 
gUt MiCRoBiota CoMpoSitioN
Sequencing of 16S bacterial RNA retrieved an overall number of 10,181,175 reads, 6,112,320 after filtering, which were clustered in 1,682 operational taxonomic units.
Alpha diversity analysis showed that the stool microbiota of patients with cirrhosis (groups 1 and 2) was less diverse compared to that of controls (Simpson's Index of Diversity groups 1 and 2: 0.15 By examining the weighted UniFrac distance, patients with cirrhosis (groups 1 and 2) and healthy controls were separated on the PCoA plot (P = 0.001), although no significant clustering was observed between patients with cirrhosis with and those without HCC (Fig. 3) .
Regarding the analysis of bacterial differential abundance, at the phylum level (Supporting Table S1 ), the gut microbiota of patients with cirrhosis (groups 1 and 2) was enriched with Proteobacteria (P adj < 0.0001), Bacteroidetes (P adj < 0.0001), and Cyanobacteria (P adj = 0.0068) compared to healthy controls (group 3), who showed instead more Verrucomicrobia (P adj = 0.0001), Tenericutes (P adj = 0.0063), and Euryarchaeota (P adj = 0.0002).
At the family level, we observed higher abundance of Lactobacillaceae (P adj < 0.0001), Pasteurellaceae (P adj < 0.0001), Enterobacteriaceae (P adj < 0.0001), Rikenellaceae (P adj < 0.0001), Prevotellaceae (P adj = 0.0017), Bacteroidaceae (P adj < 0.0001), Porphyromonadaceae (P adj = 0.0003), Barnesillaceae (P adj = 0.0051), Streptococcaceae (P adj < 0.0001), Enterococcaceae (P adj = 0.0396), and Veillonellaceae (P adj = 0.0034) in the population of patients with cirrhosis (groups 1 and 2) compared to healthy controls (group 3), whose fecal microbiota was instead mainly composed of Verrucomicrobiaceae (P adj = 0.0012) and Methanobacteriaceae (P adj = 0.0095).
At the genus level, patients with cirrhosis (groups 1 and 2) showed a higher prevalence of Lactobacillus (P adj < 0.0001), Haemophilus (P adj < 0.0001), Klebsiella The intensity of color represents the strength of the correlation. Abbreviations: FGF, fibroblast growth factor; GCSF, granulocyte colony-stimulating factor; GMCSF, granulocyte-macrophage colony-stimulating factor; IFN, interferon; TNF, tumor necrosis factor.
(P adj = 0.0013), Prevotella (P adj = 0.0006), Parabacteroides (P adj < 0.0001), Phascolarctobacterium (P adj = 0.0013), Veillonella (P adj = 0.0009), Enterococcus (P adj = 0.0047), Pseudomonas (P adj = 0.0070), Streptococcus (P adj < 0.0001), Bacteroides (P adj < 0.0001), Atopobium (P adj = 0.0037), Dialister (P adj = 0.0301), Ruminococcus (P adj < 0.0001), and Christensenella (P = 0.0456) and a reduction in Akkermansia (P adj = 0.0175) and Methanobrevibacter (P adj = 0.0114) compared to healthy controls (group 3).
The presence of HCC (group 1 versus group 2) was associated with increased abundance of Bacteroidetes at the phylum level (P adj = 0.0026); Bacteroidaceae (P adj = 0.0317), Streptococcaceae (P adj = 0.0043), Enterococcaceae (P adj = 0.0043), and Gemellaceae (P adj = 0.0317) at the family level; and Phascolarctobacterium (P adj = 0.0264), Enterococcus (P adj = 0.0176), Streptococcus (P adj = 0.0264), Gemella (P adj = 0.0473), and Bilophila (P adj = 0.0435) at the genus level, together with a reduced abundance of Verrucomicrobiaceae (P adj = 0.0317), Bifidobacteriaceae (P adj = 0.0317), Akkermansia (P adj = 0.0473), Bifidobacterium (P adj = 0.0473), Dialister (P adj = 0.0473), Collinsella (P adj = 0.0251), and Adlercreutzia (P adj = 0.0473).
To confirm both statistical and biological taxonomic differences between the gut microbiota of patients with cirrhosis and that of controls, the LEfSe algorithm with a logarithmic LDA score cutoff ≥2.0 was then performed. At the family and genus levels, patients with cirrhosis (groups 1 and 2) had increased abundance of RF39, Granulicatella, Gemella, Roseburia, Veillonella, Parabacteroides, Pseudomonas, Bacteroides, Klebsiella, Streptococcus, Blautia, Atopobium, Enterobacteriaceae, Haemophilus, Ruminococcus, Prevotella, Collinsella, and Lactobacillus, whereas increased abundance of Akkermansia, Methanobrevibacter, and Dehalobacterium was found in healthy controls (group 3) (Fig. 4) . The gut microbiota of the HCC group (group 1) was enriched with Bacteroides, Ruminococcaceae, Enterococcus, Phascolarctobacterium, and Oscillospira compared to patients with cirrhosis but without HCC (group 2) and was deficient in Bifidobacterium and Blautia (Fig. 5 ). When patients with HCC (group 1) were compared to controls (group 3), differential features similar to those obtained comparing the whole group of patients with cirrhosis to controls were observed, except for reduced abundance of Bifidobacterium (Supporting Fig. S1 ). The model, presented in Fig. 6 , highlighted an inverse correlation between the abundance of Akkermansia and fecal calprotectin (-0.260, P = 0.024), together with a direct correlation between Akkermansia and Bifidobacterium abundance (0.308, P = 0.007). Notably, the former was the most represented bacterium in the control group and the latter the most represented in patients with cirrhosis without HCC. Calprotectin was directly associated with CCL5 (0.278, P = 0.016) and IL8 (0.250, P = 0.03) plasma levels as well as with increased frequency of activated circulating monocytes (CD14   +   PDL1 + 0.479, P < 0.0001; CD14 + DR + PDL1 + 0.492, P < 0.0001; CD14 + DR + PD1 + 0.374, P = 0.001). Importantly, Bacteroides, which was mainly found in patients with cirrhosis with HCC, was directly associated with IL8 (0.286, P = 0.013) and IL13 (0.318, P = 0.005), activated circulating monocytes (CD14 + PDL1 + 0.252, P = 0.029, CD14 + DR + PDL1 + 0.277, P = 0.016; CD14 + DR + PD1 + 0.510, P < 0.0001), and mMDSC (CD14 + DR low/neg PD1 + 0.463, P < 0.0001). Altogether, these results suggest that in patients with NAFLD-related cirrhosis and HCC intestinal inflammation correlates with humoral and cellular parameters of systemic inflammation and that this inflammatory landscape is influenced by the particular composition of the gut microbiota.
CoRRelatioNS BetWeeN tHe gUt MiCRoBiota, iNteStiNal peRMeaBility, iNFlaMMatoRy paRaMeteRS, aND pBMCs iN patieNtS WitH HCC

Discussion
HCC arising in the setting of NAFLD has been linked to the systemic inflammatory status, which is typical of metabolic diseases. The gut microbiota has been recently proposed as a possible cofactor for hepatocarcinogenesis in preclinical models. (2) (3) (4) 7) With the present study, we have demonstrated a possible implication of the gut-liver axis in this process.
First of all, we observed that NAFLD patients with cirrhosis with HCC have an enhanced intestinal inflammatory status compared to those without HCC and healthy subjects, as demonstrated by the increased fecal calprotectin concentration. Calprotectin is an intracellular protein of the myeloid lineage cells, which is used as a surrogate marker of intestinal inflammation and has been shown to be increased in patients with cirrhosis in association with the severity of the disease. (17) We have also confirmed that intestinal permeability is increased in patients with compensated liver cirrhosis, as depicted by the increased ZO1 and LPS plasma levels, regardless of the presence of HCC. (18) Taken together, these data suggest that gut-derived inflammation is greater in patients with cirrhosis and HCC than in those without HCC, despite a similar degree of intestinal barrier dysfunction, which remains a key feature of liver cirrhosis.
Because gut-derived inflammation has a direct effect on the liver through the portal vein and spreads to the systemic circulation, we subsequently analyzed the patterns of cytokine and chemokine plasma levels between the study groups and observed a specific inflammatory milieu in the HCC group. Indeed, IL5, IL17, CCL2, CCL3, CCL5, CXCL10, and PDGF BB were found to be differentially expressed in the whole population of patients with cirrhosis compared to controls, whereas IL8, IL13, CCL3, CCL4, and CCL5 were significantly increased in the presence of HCC and, within the HCC group, their plasma levels correlated with circulating activated monocytes and mMDSCs.
This result is in line with the conclusions of several experimental studies. Indeed, CCL3, CCL4, and CCL5 are chemoattractant cytokines involved in the activation of a wide range of immune cells, such as monocytes, basophils, eosinophils, T cells, natural killer cells, and dendritic cells, and are well-known key players in the process of fibrosis progression and hepatocarcinogenesis. (19) (20) (21) (22) (23) (24) (25) Studies have reported higher levels of circulating CCL5 in patients with NAFLD. (26, 27) CCL5 overexpression in the liver of mouse models of NAFLD mediates the migration of gut-derived lymphocytes from mesenteric lymph nodes, resulting in liver injury and hepatic CD4 + T and CD8 + T-cell activation. (28) In a mouse model of nonalcoholic steatohepatitis (NASH), the secretion of CCL5 by Kupffer cells was increased and associated with hepatic neutrophil infiltration prior to the development of steatosis or HCC. Moreover, mice treated with CCL5 neutralizing antibodies were protected from the appearance of new HCC nodules and showed reduced growth of the already developed tumors compared to untreated controls. This was associated with a decrease of neutrophil infiltration in both tumor and adjacent liver tissue. These findings were confirmed on human tissue samples of NASH-derived HCC, where CCL5 was expressed in both hepatocytes and immune infiltrating cells compared to normal liver. (29) Interestingly, the activation of TLR4 by LPS is one of the most relevant inflammatory stimulations that can enhance the expression of CCL3, CCL4, and CCL5 by hepatic stellate cells and monocytes. (30, 31) As already described, LPS-TLR4 interaction plays a crucial role in hepatocarcinogenesis. (2) (3) (4) IL8 has been associated with HCC development, tumor burden, progression, and prognosis. (32) (33) (34) Similar to what has been reported for CCL2, CCL3, and CCL5, in mouse models the activation of hepatic stellate cells through TLR4 leads to the secretion of CXCL1, the homologue of human IL8, causing neutrophil recruitment to the liver. (35) Similar mechanisms have been postulated to promote MDSC recruitment to the liver, favoring HCC progression. (6) Finally, CCL2, CCL3, CCL5, and IL8 are secreted by tumor cells as chemoattractant mediators for MDSCs, which are immature myeloid cells involved in tumor-induced suppression of the innate and adaptive immune response. (36) IL13, which was increased in the HCC group, can activate MDSCs inducing intracellular signaling pathways such as signal transducer and activator of transcription 1 (STAT1), STAT6, and nuclear factor-κB, thus being involved in tumor progression through immunosuppressive effects. (37) To further investigate the origin of this local and systemic inflammatory status, we conducted a 16S RNA-based metagenomic analysis of the gut microbial composition.
As observed in previous studies, we confirmed that NAFLD patients with cirrhosis have a low gut microbial diversity compared to controls, (38, 39) with no difference between patients with cirrhosis with and those without HCC. However, the ordination analysis outlined a clear difference in the overall gut microbial composition of patients with cirrhosis compared to controls, while the presence of HCC was not associated with a specific operational taxonomic unit distribution. These findings suggest that the presence of cirrhosis is the pivotal factor affecting the overall composition of the gut microbiota, although specific differences in bacterial abundance can distinguish patients with or without HCC.
In particular, increased abundance of Bacteroides, Klebsiella, Blautia, Enterobacteriaceae, Streptococcus, and Ruminococcus was found in the whole group of patients with cirrhosis. This observation confirms that Enterobacteriaceae and Streptococcus represent the core flora in the gut of subjects with cirrhosis; however, only a small percentage of patients with NAFLD have been enrolled in the previously published studies in this field, and the ethnicity difference makes data difficult to compare. (38, 39) A recent study focusing only on patients with NAFLD confirms that an increase in gram-negative bacteria occurs in the advanced fibrosis stage. (40) Because this study includes only Caucasian subjects, it could become a reference for this ethnicity of patients with cirrhosis with NAFLD.
The genera Bacteroides (40, 41) and Ruminococcus (40) have been associated with NAFLD, especially in patients with advanced fibrosis. Based on the LEfSe model, the abundance of Bacteroides and Ruminococcaceae was higher in patients with cirrhosis with HCC than in those without, suggesting a role in the progression of the disease through increased inflammation, liver injury, and protumorigenic stimulation. Furthermore, patients with cirrhosis showed a lower abundance of Akkermansia compared to controls, and in patients affected by HCC also Bifidobacterium was depleted. Akkermansia and Bifidobacterium have protective effects on liver injury, reinforce gut barrier function, and reduce inflammation. (42, 43) A direct effect of the gut microbiota, and namely of Bifidobacterium, on the modulation of antitumor response has been recently proposed. (44) Nevertheless, the administration of probiotics has been demonstrated to reduce the incidence and growth of HCC lesions in mice, modulating the gut microbiota composition and restoring intestinal permeability. (4, 7) Therefore, the combined deficiency of beneficial bacteria such as Akkermansia and Bifidobacterium can enhance intestinal and liver inflammation, influencing the initiation and/or the progression of hepatocarcinogenesis.
Finally, the analysis of correlation network helped to represent the interactions between gut, liver, and immune system compartments. The inverse association between Akkermansia and fecal calprotectin confirmed that the depletion of this bacterium leads to increased intestinal inflammation; furthermore, Akkermansia and Bifidobacterium were directly correlated with each other, suggesting that the lack of both of them contributes to the development of a more marked inflammatory intestinal environment. Fecal calprotectin concentration was also directly associated with expression of CCL5, representing a possible link between intestinal inflammation, activation of the monocytic PBMCs, and the presence of HCC. Interestingly, the increase in Bacteroides abundance was associated with increased levels of the proinflammatory cytokines IL8 and IL13, circulating activated monocytes, and mMDSCs, suggesting a cofactorial role in hepatocarcinogenesis. Indeed, it has been reported that the association between Bacteroides and a Western-type diet has a proinflammatory effect, which is involved in the pathogenesis of NASH but can also contribute to the development of HCC during the natural history of the disease. (41) Nevertheless, intestinal inflammation not only may be associated with the promotion of cancer through liver injury per se but also may contribute to the suppression of immunological surveillance mechanisms in which activated monocytes, the expression of PD1 and PDL1, and mMDSCs are involved. (5, (45) (46) (47) Altogether, these data link the gut microbiota with immune modulation, which can significantly affect the process of hepatocarcinogenesis.
The major limitation of the present study is the small number of patients included. This was mainly due (1) to the choice of very restrictive inclusion criteria, which, however, allowed us to reduce the number of confounding factors, and (2) to the fact that among patients with NAFLD-related cirrhosis the incidence of HCC ranges from 2.4% over 7 years to 12.8% over 3 years of follow-up. (48, 49) In conclusion, patients with cirrhosis with NAFLD and HCC lack protective bacteria and have an enhanced intestinal inflammation compared to patients with cirrhosis without HCC. This may favor the emergence of a local microenvironment promoting hepatocarcinogenesis through the increased expression of proinflammatory cytokines and chemokines and the activation of the monocytic PBMC compartment. However, it is not yet clarified whether these alterations can vary according to the stage of the disease or if they may be associated with specific tissue or metabolic changes. Further longitudinal studies exploring the biomolecular natural history of HCC in NAFLD-related cirrhosis and the possible preventive effect of gut microbiota-modulating agents (e.g., probiotics, fecal microbiota transplantation) are warranted to confirm the translational implications of these findings in clinical practice.
